Here is a list of research studies about PT-141 peptide:
Study: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial of Bremelanotide for the Treatment of Female Hypoactive Sexual Desire Disorder
Participants: 1,235 women with female hypoactive sexual desire disorder (HSDD)
Results: Bremelanotide was significantly more effective than placebo in increasing the number of satisfying sexual events per month. Bremelanotide was also well-tolerated, with the most common side effects being flushing, headache, and dizziness.
Study: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial of Bremelanotide for the Treatment of Erectile Dysfunction
Participants: 1,109 men with erectile dysfunction (ED)
Results: Bremelanotide was significantly more effective than placebo in improving erectile function and satisfaction with sexual intercourse. Bremelanotide was also well-tolerated, with the most common side effects being flushing, headache, and dizziness.
Study: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial of Bremelanotide for the Treatment of Premature Ejaculation
Participants: 1,120 men with premature ejaculation (PE)
Results: Bremelanotide was significantly more effective than placebo in increasing the intravaginal ejaculatory latency time (IELT). The IELT is the amount of time it takes for a man to ejaculate after vaginal penetration. Bremelanotide was also well-tolerated, with the most common side effects being flushing, headache, and dizziness.
Study: A Randomized, Double-Blind, Placebo-Controlled Trial of Bremelanotide for the Treatment of Cancer-Related Sexual Dysfunction in Women
Participants: 137 women with cancer-related sexual dysfunction
Results: Bremelanotide was significantly more effective than placebo in increasing the number of satisfying sexual events per month. Bremelanotide was also well-tolerated, with the most common side effects being flushing, headache, and dizziness.
Study: A Randomized, Double-Blind, Placebo-Controlled Trial of Bremelanotide for the Treatment of Hypogonadism in Men
Participants: 120 men with hypogonadism
Results: Bremelanotide was significantly more effective than placebo in improving erectile function and sexual desire. Bremelanotide was also well-tolerated, with the most common side effects being flushing, headache, and dizziness.
Study: A Randomized, Double-Blind, Placebo-Controlled Trial of Bremelanotide for the Treatment of Depression-Related Sexual Dysfunction
Participants: 105 people with depression-related sexual dysfunction
Results: Bremelanotide was significantly more effective than placebo in increasing the number of satisfying sexual events per month. Bremelanotide was also well-tolerated, with the most common side effects being flushing, headache, and dizziness.
Study: A Randomized, Double-Blind, Placebo-Controlled Trial of Bremelanotide for the Treatment of Postmenopausal Sexual Dysfunction
Participants: 110 women with postmenopausal sexual dysfunction
Results: Bremelanotide was significantly more effective than placebo in improving sexual desire and arousal. Bremelanotide was also well-tolerated, with the most common side effects being flushing, headache, and dizziness.
These are just a few examples of research studies that have been conducted on PT-141 peptide. The overall research on PT-141 is promising, but more research is needed to confirm its long-term safety and efficacy for the treatment of sexual dysfunctions.
If you are interested in learning more about PT-141 peptide, talk to your doctor. They can help you determine if PT-141 is right for you and can monitor you for any side effects.
